Skip to content
IP + Technology Law
Home  »  News & Insights  »  Publications

Lessons From The 1st Biopharma Inter Partes Reviews | Law360

April 16, 2015  | Eli A. Loots, Ph.D.

Recently, the Patent Trial and Appeal Board issued its first set of final written decisions in three inter partes reviews relating to molecules in the large molecule biopharma space (IPR2013-00534, IPR2013- 00535 and IPR2013-00537). Biosimilar companies will no doubt be looking to these decisions as a roadmap for clearing patent landscapes for their own biosimilar products in the coming years. Read more below or download the PDF.

Lessons From The 1st Biopharma Inter Partes Reviews from Knobbe Martens Olson & Bear

Related Links

Practice Areas

Industries

News & Insights

Publications
Nov 2025
Jeremiah Helm and Sean Murray’s Discuss Extension of Printed Matter Doctrine in Law360 Column
In their latest Law360 column discussing noteworthy Federal Circuit cases, partners Jeremiah Helm and Sean Murray examine the recent decision in Bayer Pharma Aktiengesellschaft v. Mylan Pharmaceuticals Inc., and how...
Blog - Aerospace
Nov 2025
Aerospace IP Strategy in View of Recent U.S. Patent Office Updates
Aerospace technology companies often decide between patenting an innovation or keeping it as a trade secret. Typically, the analysis involves comparing the potential strength of patent protection that is likely...
News
Sep 2025
Joseph Re Quoted by Law360 on Potential Policy Initiatives Under New USPTO Director
In the Law360 article “Squires Confirmation Has Patent Attys Hoping For Stability,” partner Joseph Re shared his perspective on which USPTO policies should be a priority for Director John Squires,...